SOLASTA Bio, a biotechnology research startup based in Glasgow, UK, has recently raised an impressive $4.96 million in pre-Series A funding from investors, including Rubio Impact, Cavallo Ventures, Scottish Enterprise, SIS Ventures, and The Yield Lab. Led by founder Shireen Davies, SOLASTA Bio is taking on the massive challenge of protecting crop yields and delivering food security while preserving the environment. Their product portfolio includes biological pesticides and neuropeptide-based insect control products, which have the potential to control a wide range of pests, including those with resistance to synthetic chemistries. 

What sets SOLASTA Bio apart is its use of neuron-made small proteins called neuropeptides instead of synthetic chemicals traditionally used in insecticides. These "nature-inspired" products can specifically target pest insects while leaving pollinators such as bees unharmed. With 94% of the insecticides market currently dominated by synthetic chemicals, SOLASTA Bio's innovative approach is poised to disrupt the industry. With plans to bring its first patent-protected product to market in 2027, SOLASTA Bio is an exciting startup to watch as they work towards a more sustainable, eco-friendly future.